Cassava’s Chief Medical Officer to retire
by
Contributor since / Followers
Contributor since / Followers
5 days ago
bankrx Cassava Sciences (NASDAQ:SAVA) announced on Monday the retirement of James W. Kupiec, Chief Medical
SAVA
4 stocks to watch on Tuesday: GME, TSLA, SAVA and CCI
by
Contributor since / Followers
Contributor since / Followers
1 month ago
Melissa Kopka U.S. stock index futures were slightly higher on Tuesday, as Wall Street looked
Cassava to phase out Alzheimer’s program by Q2
by
Contributor since / Followers
Contributor since / Followers
1 month ago
travellinglight/iStock via Getty Images Cassava Sciences (NASDAQ:SAVA) lost ~19% in the premarket on Tuesday after
Cassava Sciences GAAP EPS of -$0.57 beats by $0.09
by
Contributor since / Followers
Contributor since / Followers
2 months ago
Cassava Sciences press release (NASDAQ:SAVA): Q4 GAAP EPS of -$0.57 beats by $0.09. At December
Cassava Sciences signs license deal with Yale University, shares up
by
Contributor since / Followers
Contributor since / Followers
2 months ago
koto_feja/E+ via Getty Images Cassava Sciences (NASDAQ:SAVA) said on Thursday that it has signed a
Cassava terminates phase 3 REFOCUS-ALZ trial for simufilam
by
Contributor since / Followers
Contributor since / Followers
3 months ago
tupungato Cassava Sciences (NASDAQ:SAVA) has formally ended its phase 3 REFOCUS-ALZ trial for Alzheimer’s asset
Cassava laying off one-third of staff to curb expenses
by
Contributor since / Followers
Contributor since / Followers
4 months ago
BrianAJackson Cassava Sciences (NASDAQ:SAVA) is laying off 33% of its workforce — 10 employees —
Cassava Sciences: REFOCUS Unlikely To Save Simufilam, Careful Development Needed
by Biotech Beast
Contributor since 2015 / 8175 Followers
Contributor since 2015 / 8175 Followers
5 months ago
Summary: Cassava Sciences’ phase 3 RETHINK study of simufilam in Alzheimer’s disease was not a
Cassava Sciences: Probably The End Of The Saga
by Tejo Strategy Investing
Contributor since 2024 / 93 Followers
Contributor since 2024 / 93 Followers
5 months ago
Summary: Cassava Sciences’ Phase 3 trial for Alzheimer’s failed to meet primary or secondary endpoints,
Cassava Sciences: Phase 3 Alzheimer’s Drug Fail The Final Nail In The Coffin
by Edmund Ingham
Contributor since 2018 / 12771 Followers
Contributor since 2018 / 12771 Followers
5 months ago
Summary: Cassava Sciences’ Alzheimer’s drug simufilam failed to meet primary, secondary, and exploratory endpoints in